drugset / Trial / NCT01025934

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

NCT01025934

Treatment

Summary

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 1.25 mg Intravitreal